THP — docetaxel + trastuzumab + pertuzumab (HER2+ metastatic 1L)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-DOCETAXEL DRUG-TRASTUZUMAB DRUG-PERTUZUMAB |
|---|
| ID | REG-THP-METASTATIC |
|---|---|
| Type | Regimen |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Notes
CLEOPATRA: median OS ~57 months (pertuzumab arm) — landmark for HER2+ metastatic. After docetaxel discontinuation (typically ~6-8 cycles or toxicity), HP maintenance continues until progression. Endocrine therapy added if HR+ co-expressed.
Used By
Handbook Chapters
HB-BREAST-HER2-POS-MET-1L- HER2+ metastatic breast cancer: first-line reasoning
Handbook Questions
HQ-BREAST-HER2-POS-1L-001- HQ-BREAST-HER2-POS-1L-001
Indication
IND-BREAST-HER2-POS-MET-1L-THP- IND-BREAST-HER2-POS-MET-1L-THP